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The P2X7 receptor is not essential for development of imiquimod-induced
psoriasis-like inflammation in mice
Abstract
Psoriasis is a chronic inflammatory skin disorder, characterised by epidermal hyperplasia (acanthosis)
and leukocyte infiltration of the skin. Current therapies are inadequate, highlighting the need for new
therapeutic targets. The P2X7 receptor is implicated in the pathogenesis of psoriasis. This study
investigated the role of P2X7 in imiquimod (IMQ)-induced psoriasis-like inflammation. Topically applied
IMQ caused twofold greater ear swelling in BALB/c mice compared to C57BL/6 mice, which encode a
partial loss-of-function missense mutation in the P2RX7 gene. However, there was no difference in
histological skin pathology (acanthosis and leukocyte infiltration) between the two strains. IMQ treatment
up-regulated P2X7 expression in skin from both mouse strains. Additionally, IMQ induced ATP release
from cultured human keratinocytes, a process independent of cell death. Injection of the P2X7 antagonist
Brilliant Blue G (BBG) but not A-804598 partly reduced ear swelling compared to vehicle-injected control
mice. Neither antagonist altered skin pathology. Moreover, no difference in ear swelling or skin pathology
was observed between C57BL/6 and P2X7 knock-out (KO) mice. Flow cytometric analysis of IMQ-treated
skin from C57BL/6 and P2X7 KO mice demonstrated similar leukocyte infiltration, including neutrophils,
macrophages and T cells. In conclusion, this study demonstrates that P2X7 is not essential for
development of IMQ-induced psoriasis-like inflammation but does not exclude a role for this receptor in
psoriasis development in humans or other mouse models of this disease.
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ABSTRACT
Psoriasis is a chronic inflammatory skin disorder, characterised by epidermal hyperplasia
(acanthosis) and leukocyte infiltration of the skin. Current therapies are inadequate,
highlighting the need for new therapeutic targets. The P2X7 receptor is implicated in the
pathogenesis of psoriasis. This study investigated the role of P2X7 in imiquimod (IMQ)induced psoriasis-like inflammation. Topically-applied IMQ caused two-fold greater ear
swelling in BALB/c mice compared to C57BL/6 mice, which encode a partial loss-offunction missense mutation in the P2RX7 gene. However, there was no difference in
histological skin pathology (acanthosis and leukocyte infiltration) between the two strains.
IMQ treatment up-regulated P2X7 expression in skin from both mouse strains. Additionally,
IMQ induced ATP release from cultured human keratinocytes, a process independent of cell
death. Injection of the P2X7 antagonist Brilliant Blue G (BBG) but not A-804598 partly
reduced ear swelling compared to vehicle-injected control mice. Neither antagonist altered
skin pathology. Moreover, no difference in ear swelling or skin pathology was observed
between C57BL/6 and P2X7 knock-out (KO) mice. Flow cytometric analysis of IMQ-treated
skin from C57BL/6 and P2X7 KO mice demonstrated similar leukocyte infiltration, including
neutrophils, macrophages and T cells. In conclusion, this study demonstrates that P2X7 is not
essential for development of IMQ-induced psoriasis-like inflammation, but does not exclude
a role for this receptor in psoriasis development in humans or other mouse models of this
disease.

KEYWORDS: P2X7 receptor, extracellular ATP, imiquimod, psoriasis, skin immune system
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INTRODUCTION
Psoriasis affects 1-3% of the general population of Western countries, reducing quality of life
and posing a significant economic burden [1]. In the USA alone, psoriasis is estimated to cost
$112 billion per year [2]. Inflammation and hyper-proliferation of keratinocytes in psoriasis
results in epidermal hyperplasia (acanthosis) and plaque- or pustular-like skin lesions [3].
This characteristic inflammation is driven by infiltrating leukocytes, including neutrophils,
macrophages and T cells [4]. These leukocytes exert their effects by release of proinflammatory cytokines such as interferon gamma (IFN-γ) [3,4], which promotes the hyperproliferation of keratinocytes, with the resulting cell damage exacerbating inflammation and
leading to plaque formation [4].
The imiquimod (IMQ)-induced psoriasis-like inflammation mouse model is a valuable model
for studying psoriasis pathogenesis. This model involves application of AldaraTM cream,
containing IMQ, which causes epidermal hyperplasia and immune infiltration similar to
psoriasis in humans [5]. IMQ treatment results in scaling and thickening of skin as well as
infiltration of immune cells 48-72 hours after first application [5]. This model has been well
characterised [6] and used in some 200 different studies to date [7].
The ATP-gated P2X7 receptor channel has been implicated in a number of skin diseases
including psoriasis [8]. P2X7 is present on keratinocytes [9] and immune cells important in
psoriasis including neutrophils [10], macrophages [11] and T cells [12], where its activation
can drive cytokine release and potentially promote inflammation [8]. Notably, IFN-γ can upregulate the expression of P2X7 in primary keratinocytes [13] and P2X7 expression is
increased in human psoriatic lesions [13,14]. A functional role for P2X7 in psoriasis has also
been suggested. Injection of the P2X7 agonist 3’-O-(4-benzoyl)benzoyl ATP into normal
human skin explants induces increased expression of cytokines and other molecules
commonly associated with psoriasis, including interleukin (IL)-1β, IL-6 and tumour necrosis
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factor alpha (TNF-α) [14]. Importantly, these responses could be prevented through
pharmacological blockade of P2X7 [14]. P2X7 activation of skin migrating dendritic cells
also promoted Th17 responses [14], a T cell subtype known to contribute to psoriasis
pathogenesis [15].
This study investigated the role of P2X7 in the pathogenesis of psoriasis using a murine
model of IMQ-induced psoriasis-like inflammation. Results indicate that P2X7 is upregulated in psoriatic skin in both BALB/c and C57BL/6 mice, which encode the wild-type
(P451) or partial loss-of function (451L) allele, respectively [16]. IMQ also induced ATP
release from human keratinocytes. However, pharmacological blockade or genetic deletion of
P2X7 showed a limited role for P2X7 in this murine model of psoriasis.
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MATERIALS AND METHODS
Cells
Human HaCaT keratinocytes and murine J774 macrophages were obtained and cultured as
described [17,18]. Cell lines were checked for Mycoplasma spp. infections every two months,
using a MycoAlertTM Mycoplasma detection kit (Lonza, Basal, Switzerland) as per the
manufacturer’s instructions. Cells were routinely negative for Mycoplasma spp.

Mice
Female and male mice (aged 6-10 weeks) were used in experiments conducted under protocol
AE14/10, which was approved by the University of Wollongong Animal Ethics Committee
(Wollongong, Australia). BALB/c and C57BL/6 mice were obtained from Australian
BioResources (Moss Vale, Australia). P2X7 knock-out (KO) mice [19] backcrossed onto a
C57BL/6 background [20], were maintained at the University of Wollongong and genotyped
as described [19]. All mice were housed in open top cages and provided with food and water,
ad libitum. All mice were housed in a temperature-controlled environment with a 12 h
light/12 h dark cycle.

Murine model of IMQ-induced psoriasis-like inflammation
A total of 25 mg of AldaraTM cream (1.25 mg IMQ) (iNova Pharmaceuticals, Thornleigh,
Australia) was applied to both sides of one ear of each mouse and the contralateral ear
remained untreated (control) (days 0-5) as described [21]. Prior to treatment mice were
weighed and ear measurements were recorded using Interapid (Rolle, Switzerland) springloaded calipers (days 0-6). In some experiments, Brilliant Blue G (BBG) or A-804598 (both
Sigma-Aldrich, St Louis, MO, USA) (final concentration 50 mg/kg in mice), and their
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respective diluent controls (saline or dimethyl sulfoxide (DMSO), respectively), were
injected every second day (as indicated). Mice were sacrificed on day 6 and ears collected.

Histological analysis
Ears from euthanised mice were incubated overnight in neutral buffered (10%) formalin
(Sigma-Aldrich). Fixed tissues were removed, embedded in paraffin, sectioned (5 µm) and
stained with haematoxylin and eosin (POCD, Artarmon, Australia). Histology was observed
using a Leica (Wetzlar, Germany) DM500 inverted light microscope, with images captured
and processed using Leica application suite software version 4.7. Acanthosis (epidermal
thickness) was measured using ImageJ software version 1.48 (National Institutes of Health,
Bethesda, MD, USA).

Isolation of RNA and cDNA synthesis
Ears from euthanised mice were stored in RNAlater (Sigma-Aldrich) at -20°C until required.
RNA was isolated using the ISOLATE II RNA Mini Kit (Bioline, London, UK) as per the
manufacturer’s instructions. Briefly, tissue in lysis buffer containing 1% (v/v) βmercaptoethanol (Sigma-Aldrich) was homogenised (two 20 second cycles at 5500 rpm) in a
Bertin Technologies (Montigny-le-Bretonneux, France) Precellys 24 tissue homogeniser.
Isolated RNA was immediately converted to cDNA using the qScript cDNA Synthesis Kit
(Quanta Biosciences, Gaithersburg, MD, USA) as per the manufacturer’s instructions. cDNA
was checked by PCR amplification of the house keeping gene glyceraldehyde 3-phosphate
dehydrogenase (Invitrogen, Carlsbad, CA, USA) for 35 cycles at 95°C for 1 min, 55°C for 1
min and 72°C for 1 min and a holding temperature of 4°C. Purity and size of amplicons were
confirmed by a 2% agarose gel electrophoresis.
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Quantitative real-time polymerase chain reaction
qPCR reactions were performed using TaqMan Universal Master Mix II (Thermo Fisher
Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s instructions with
primers for FAM-labelled GAPDH (Mm99999915_g1) and VIC-labelled P2RX7
(Mm01199503_m1) (Thermo Fisher Scientific). qPCR cycles consisted of an initial step of
50°C for 2 min, followed by 50°C for 10 min, and 40 cycles at 95°C for 15 s, and 60°C for 1
min. qPCR reactions were conducted in triplicate on a Roche Diagnostics (Indianapolis, IN,
USA) LightCycler 480 and analysis was conducted using LightCycler480 software version
1.5.1.

ATP release assay
ATP release assays were performed as described [22]. Briefly, HaCaT keratinocytes were
plated in 12-well plates (Greiner Bio-One, Frickenhausen, Germany) at a concentration of 2 x
105 cells/well in RPMI 1640 medium containing 2 mM L-glutamine, 1% non-essential amino
acids (all Thermo Fisher Scientific), and 10% (v/v) heat-inactivated foetal bovine serum
(Bovogen Biologicals, Keller East, Australia), and incubated for 24 h at 37°C/5% CO2. Cells
were washed thrice with PBS (Thermo Fisher Scientific), and incubated in 1 mL PBS
containing DMSO or 1 µg/mL IMQ (Sigma-Aldrich) in DMSO for 30 min at 37°C/5% CO2.
The final concentration of DMSO in both groups was 0.1%. Cells were then centrifuged
through 10% bovine serum albumin (4,000 x g for 3 min) and cell free supernatants were
stored in duplicate at -20°C until required. ATP concentrations in supernatants were assessed
using a Bioluminescence ATP Assay Kit (Sigma-Aldrich) as described [23]. The amount of
lactate dehydrogenase (LDH) in supernatants was determined using a Cytotoxicity Detection
Kit (LDH) (Roche Diagnostics) as per the manufacturer’s instructions using a Molecular
devices (Sunnyvale, CA, USA) Spectramax Plus 384 plate reader.
7
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ATP-induced ethidium+ uptake assay
P2X7 pore formation was quantified by measuring ATP-induced ethidium+ uptake as
described [24]. Briefly, J774 cells in NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM
glucose and 10 mM HEPES, pH 7.5) were pre-incubated in the absence or presence of BBG
or A-804598 (as indicated) for 15 min at 37°C. Cells were then incubated with 25 µM
ethidium bromide (Sigma-Aldrich) in the absence or presence of 1 mM ATP (Sigma-Aldrich)
for 10 min. Incubations were stopped by addition of ice-cold NaCl medium containing 20
mM MgCl2 (MgCl2 medium) and cells were washed with NaCl medium (300 x g for 3 min).
Data was collected using a BD Biosciences (San Jose, CA, USA) LSRFortessa X-20 flow
cytometer (using band-pass filter 530/30 for ethidium+) and FACSDiva software version 8.0.
Mean fluorescence intensity (MFI) of ethidium+ uptake was analysed using FlowJo software
version 8.7.1. (TreeStar Inc., Ashland, OH, USA).

Immunophenotyping
CD16/32 Fc Block (clone 2-4G2), Brilliant Violet (BV)450-conjugated rat anti-mouse Ly-6G
(clone 1A8), peridinin chlorophyll protein (PerCP)-conjugated rat anti-mouse CD4 (clone
RM4.5), allophycocyanin (APC)-conjugated rat anti-mouse CD45 (clone 30-F11) and Rphycoerythrin (PE)-Cy7 conjugated hamster anti-mouse CD3e (clone 145-2C11) were from
BD Biosciences. PE-conjugated rat anti-mouse CD11b (clone M1/70) was from BioLegend
(San Diego, CA, USA).
Enzymatic digestion of ears was performed as described [25]. Briefly, dorsal and ventral
sides of ears were separated and incubated in 20 mM EDTA (Sigma-Aldrich) in Tris-buffered
saline (pH 7.3) for 2 hours at 37°C. Epidermal and dermal layers were mechanically
separated, cut into smaller fragments using a scalpel and homogenised in RPMI 1640
medium containing 1 mg/mL collagenase IV and 15 U/mL DNase I (both Sigma-Aldrich),
8
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and 5% heat-inactivated foetal bovine serum at room temperature for 90 min with agitation.
Enzymatic digestion was stopped by addition of 100 mM EDTA and suspensions filtered
through 70 µm cell strainers (Falcon, Franklin, NJ, USA). Cells were centrifuged (300 x g for
5 min), resuspended in PBS and counted manually using a Boeco (Hamburg, Germany)
Neubauer Improved Bright Line haemacytometer. Cells were incubated with CD16/32 Fc
Block for 10 min and then with fluorochrome-conjugated monoclonal antibodies in the dark
for 10 min. Cells were washed twice with PBS (300 x g for 3 min), resuspended in PBS and
data was collected using a LSRFortessa X-20 flow cytometer (using band pass filters 450/50
for BV421, 695/40-A for PerCP, 575/25-A for PE, 780/60 for PE-Cy7 and 670/30 for APC)
and FACSDiva software. The relative percentage of cells was analysed using FlowJo
software.

Statistical Analysis
Data is given as mean ± standard error of the mean (SEM). Statistical differences were
calculated using Student’s t test for single comparisons or one-way analysis of variance
(ANOVA) with Tukeys post-hoc test for multiple comparisons. Weight and ear
measurements were analysed using a repeated measures two-way ANOVA. All statistical
analyses and graphs were generated using Prism 5 for Windows software (GraphPad
Software, La Jolla, CA, USA).
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RESULTS
IMQ treatment induces greater ear swelling in BALB/c mice compared to C57BL/6
mice
To investigate the role of P2X7 in psoriasis, IMQ-induced psoriasis-like inflammation was
first compared over 6 days in BALB/c and C57BL/6 mice. C57BL/6 mice encode a loss-offunction mutation (P451L) in the P2RX7 gene, while BALB/c mice are wild-type at this
allele [16]. IMQ induced ear swelling in ears relative to control (contralateral untreated) ears
from day 3 in both strains (Fig. 1a). However, IMQ-induced ear swelling was greater in
BALB/c mice compared to C57BL/6 mice over 6 days (P < 0.0001) (Fig. 1a). Histological
analysis of IMQ-treated ears from BALB/c and C57BL/6 mice demonstrated acanthosis
(epidermal thickening) and leukocyte infiltration compared to control ears; however, there
was no difference between strains (Fig. 1b). Image analysis of histological sections revealed
that epidermal thickness was significantly greater in IMQ-treated ears compared to control
ears from both BALB/c mice (P < 0.0001) and C57BL/6 mice (P < 0.0001). However, IMQinduced epidermal thickening did not significantly differ between the two strains (Fig. 1c).

P2X7 mRNA is up-regulated in IMQ-induced psoriatic lesions and IMQ induces ATP
release from keratinocytes
Next, P2X7 mRNA expression in IMQ-treated and control ears was analysed by qPCR. P2X7
was significantly up-regulated almost three-fold and two-fold in IMQ-treated ears compared
to control ears from BALB/c mice (P = 0.0002) and C57BL/6 mice (P = 0.0343),
respectively (Fig. 2a). To further determine a potential role for P2X7 activation in IMQinduced psoriasis-like inflammation, HaCaT keratinocytes were incubated in the presence of
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1 µg/mL IMQ or DMSO (vehicle control) for 30 min and the amount of ATP released
measured using a bioluminescence assay. IMQ induced significantly greater amounts of ATP
release compared to DMSO (P = 0.0425) (Fig. 2b). To examine if this ATP release was due
to cytotoxicity by IMQ, the relative amount of LDH in the above supernatants was
determined using a spectrophotometric assay. Although the absorbance in the IMQ cells was
reduced the absorbance values were not significantly different between IMQ and control
groups (Fig. 2c).

BBG does not prevent IMQ-induced psoriasis-like inflammation
To investigate the role of P2X7 in IMQ-induced psoriasis-like inflammation, the P2X7
antagonist BBG [26] was used in this model. First, to confirm that BBG can impair murine
P2X7 activation, J774 macrophages, which express functional P2X7 [27], were pre-incubated
in the absence or presence of 10 µM BBG and ATP-induced cation dye uptake was measured
by flow cytometry. BBG significantly reduced ATP-induced ethidium+ uptake by 87% (P <
0.0001) (Fig. 3a). To determine if BBG could prevent the development of IMQ-induced
psoriasis-like inflammation BALB/c mice were treated with IMQ as above and injected with
BBG or saline (vehicle control) every second day (days 0, 2 and 4). IMQ induced ear
swelling in mice from day 3 regardless of treatment. However, IMQ-induced ear swelling
was partially reduced (by 21%) in BBG-injected mice compared to saline-injected mice over
6 days (P = 0.0068) (Fig. 3b). Histological analysis of IMQ-treated ears from BBG- and
saline-injected mice demonstrated epidermal thickening and leukocyte infiltration compared
to control ears; but there were no differences between BBG and saline treatments (Fig. 3c).
Image analysis of histological sections revealed that epidermal thickness was greater in IMQtreated ears compared to control ears from BBG-injected mice (P < 0.0001) and saline11
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injected mice (P < 0.0001). Epidermal thickness in IMQ-treated and control ears was similar
between BBG and saline treatments (Fig. 3d).

A-804598 does not prevent IMQ-induced psoriasis-like inflammation
To further examine the potential effects of P2X7 blockade on psoriasis-like inflammation, the
P2X7 antagonist A-804598 [28] was used. Similar to BBG, A-804598 near-completely
abrogated ATP-induced ethidium+ uptake in J774 macrophages (P < 0.0001) (Fig. 4a).
BALB/c mice were treated with IMQ as above and injected with A-804598 or DMSO
(vehicle control) every second day (days 0 and 2). IMQ induced ear swelling in mice from
day 3 regardless of treatment. A-804598- and DMSO-injected mice demonstrated similar ear
swelling (Fig. 4b). Histological analysis of IMQ-treated ears from A-804598-injected and
DMSO-injected mice demonstrated epidermal thickening and leukocyte infiltration compared
to control ears with no difference between A-804598 and control treatments (Fig. 4c). Image
analysis of histological sections revealed that epidermal thickness was greater in IMQ-treated
ears compared to control ears from A-804598-injected mice (P < 0.0001) and DMSOinjected mice (P < 0.0001). Epidermal thickness in IMQ-treated and control ears was also
similar between A-804598 and control treatments (Fig. 4d).

Genetic deletion of P2X7 does not prevent IMQ-induced psoriasis-like inflammation
Finally, to determine if genetic deficiency of P2X7 could alter IMQ-induced psoriasis-like
inflammation, C57BL/6 and P2X7 KO mice were treated with IMQ as above. Both C57BL/6
and P2X7 KO mice demonstrated ear swelling in IMQ-treated ears from day 3, but this was
not significantly different between the two strains over 6 days (Fig. 5a). Histological analysis
of IMQ-treated ears from C57BL/6 and P2X7 KO mice demonstrated epidermal thickening
and leukocyte infiltration compared to control ears, with no difference between strains (Fig.
12
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5b). Image analysis of histology revealed that epidermal thickness was significantly greater in
IMQ-treated ears compared to control ears from C57BL/6 mice (P < 0.0001) and P2X7 KO
mice (P < 0.0001). Epidermal thickness in IMQ-treated and control ears was also similar
between C57BL/6 and P2X7 KO mice (Fig. 5c).

IMQ-induced leukocyte infiltration is similar in C57BL/6 and P2X7 KO mice
The data above indicates that P2X7 deficiency does not prevent IMQ-induced psoriasis-like
inflammation in mice. However, the possibility remained that P2X7 deficiency may have
altered the number of leukocyte subsets infiltrating the skin in this disease model. Therefore,
whole ear cell suspensions of IMQ-treated and control ears from C57BL/6 and P2X7 KO
mice were examined by flow cytometry. IMQ induced a significant increase in total skin
leukocytes in both C57BL/6 (P = 0.0002) and P2X7 KO (P = 0.0029) mice, but there was no
significant difference between strains (Figure 6a). Subset analysis also revealed IMQ induced
a significant increase in neutrophils and macrophages in both C57BL/6 (P = 0.0027 and P <
0.0001, respectively) and P2X7 KO (P = 0.0020 and P = 0.0046, respectively) mice, but there
was no significant difference between strains (Figure 6b-c). IMQ induced a significant
increase in T cells in C57BL/6 (P = 0.0006) but not P2X7 KO mice; yet there was no
significant difference between strains (Figure 6d).
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DISCUSSION
This study demonstrated that P2X7 is not essential for the development of IMQ-induced
psoriasis-like inflammation in mice. With the exception of a partial effect on ear swelling by
BBG, pharmacological blockade or genetic deletion of P2X7 did not impact development of
IMQ-induced psoriasis-like inflammation. The general lack of effect of either P2X7
antagonist was not due to the preparations of BBG or A-804598, as both compounds blocked
ATP-induced dye uptake into murine macrophages in this study. Moreover, both compounds
were used in vivo at concentrations known to inhibit murine P2X7 [29]. In regards to IMQinduced ear swelling, BBG may be blocking alternate molecules, such as P2X1 [30], P2X5
[31], the ATP channel pannexin-1 [32] or a voltage-gated sodium channel [33].
Genetic deficiency of P2X7 did not impact leukocyte infiltration in IMQ-induced psoriasislike inflammation. In contrast, a previous study reported that P2X7 KO mice had reduced
neutrophil infiltration into skin in a croton oil model of irritant contact dermatitis [34].
However, in line with our current study, ear swelling was similar between wild-type and
P2X7 KO mice in croton oil-induced irritant contact dermatitis [34,35]. Conversely, P2X7
KO mice are protected from allergic contact dermatitis, which was also assessed by ear
swelling measurements [35]. This previous study demonstrated that P2X7-mediated IL-1β
release, which requires NLRP3 inflammasome activation [36], was essential for allergic
contact dermatitis [35]. In contrast, activation of the NLRP3 inflammasome is not required
for IMQ-induced psoriasis-like inflammation [37]. Thus, this provides a possible explanation
as to why P2X7 is not essential in this model of psoriasis. Collectively, this indicates P2X7
plays differing roles in various inflammatory skin disorders, but given previous findings
[13,14] further investigation of P2X7 in human psoriasis and other mouse models of this
disease is warranted. Moreover, it should be noted that C-terminal truncated P2X7 variants
are present at low amounts in C57BL/6 and Pfizer P2X7 KO mice [38], the same strains used
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in the current study. Although P2X7-induced pore formation is absent in splenic T and B
cells [39], epidermal Langerhans cells and keratinocytes [20] from these P2X7 KO mice, a
role for these escape P2X7 variants in IMQ-induced psoriasis-like inflammation in P2X7 KO
mice cannot be excluded. P2X7 KO strains in which escape variants have not been reported,
such as those from Lexicon Pharmaceuticals [40] or conditional humanised P2X7 KO mice
[41], provide alternatives to assess the potential role of P2X7 in psoriasis.
Ear swelling, but not histological acanthosis or inflammation, differed between BALB/c and
C57BL/6 mice. Thus, this difference in ear swelling most likely reflects differences in
oedema. Coincidentally, this difference in ear swelling corresponds to P2RX7 genotype
(P451L mutation), but P2X7 deficiency in mice on a C57BL/6 background does not alter ear
swelling compared to wild-type C57BL/6 mice. This suggests that the difference between
BALB/c and C57BL/6 mice is not due to reduced P2X7 activity as a result of the P451L
mutation in C57BL/6 mice. In this regard, whilst some have reported that the P451L mutation
results in a loss of P2X7 activity [16,42], others have observed no differences in the activity
or pharmacological profiles between recombinant BALB/c and C57BL/6 P2X7 [43].
Moreover, it remains to be established if P2X7 variants differ between BALB/c and C57BL/6
mice, and if P2X7 activity differs between these two mouse strains in vivo. BALB/c and
C57BL/6 mice have a diverse lineage and display phenotypic and genetic differences [44,45].
Thus, differences in IMQ-induced ear swelling between these strains could be due to any
number of genotypic or phenotypic differences. Notably, IL-22 expression is increased in
IMQ-induced psoriasis-like inflammation in BALB/c, but not C57BL/6, mice [5].
Conversely, IL-6 is detected in C57BL/6 mice, but not BALB/c mice [5]. Thus, a role for
these cytokines in oedema during psoriasis warrants further investigation.
Analysis by qPCR revealed P2X7 mRNA expression was up-regulated in IMQ-treated skin in
both BALB/c and C57BL/6 mice. Although, it was not determined if P2X7 protein is
15
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increased in these mice, P2X7 protein is increased in lesional skin from psoriasis patients
[13,14]. Notably, P2X7 is up-regulated on human keratinocytes by IFN-γ [13], a cytokine
implicated in psoriasis pathogenesis [46] including IMQ-induced psoriasis-like inflammation
[5]. Therefore, P2X7 may be up-regulated on keratinocytes due to IFN-γ present in IMQtreated skin. Alternatively, since P2X7 is also found on various skin immune cells [8],
increased P2X7 expression in IMQ-treated ears may simply reflect increased numbers of
infiltrating leukocytes in IMQ-induced skin as observed in the current study.
Finally, this study demonstrated that HaCaT keratinocytes can constitutively release ATP, as
previously observed [47], and that this release could be increased by IMQ. The IMQ-induced
ATP release was not due to cytotoxicity, as IMQ did not significantly alter LDH release.
Although genetic deletion or pharmacological blockade of P2X7 did not impact IMQ-induced
psoriasis-like inflammation in this study, extracellular ATP may be involved in the
development of this disease through activation of purinergic receptors other than P2X7. In
particular, P2Y1, P2Y2 and P2Y6 have been implicated in psoriasis or other inflammatory
skin conditions [48].
In conclusion, pharmacological blockade and genetic deletion of P2X7 could not prevent
IMQ-induced psoriasis-like inflammation. However, given the potential roles of P2X7 in
human psoriasis [13,14] and other skin diseases [8], a role for this receptor in human
psoriasis or other mouse models of this disease cannot be excluded.
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FIGURE LEGENDS
Figure 1 IMQ treatment induces greater ear swelling in BALB/c mice compared to
C57BL/6 mice.
(a-b) AldaraTM cream (containing 5% IMQ) was applied to one ear of BALB/c and C57BL/6
mice from day 0 to 5. Contralateral ears were left untreated (control). (a) Ear swelling was
measured over 6 days. Data represents group means ± SEM (n = 14 per strain). *** P <
0.0001 compared to C57BL/6. (b) Ears from mice at end-point were stained with
haematoxylin and eosin, and viewed by microscopy. Each image is representative of 14 mice
per group. Bars represent 200 µm. (c) Epidermal thickness was measured on histological
images using ImageJ. Data represents group means ± SEM (n = 14 mice per group); symbols
represent individual ears; *** P < 0.0001 compared to corresponding control.

Figure 2 P2X7 is up-regulated in IMQ-treated skin and IMQ can induce ATP release
from keratinocytes.
(a) P2X7 expression in untreated (control) and IMQ-treated ears from BALB/c and C57BL/6
mice at end-point (Fig. 1) was assessed by qPCR. Data represents group means ± SEM (n = 5
mice per strain); symbols represent individual ears; * P < 0.05, *** P < 0.0001 compared to
corresponding control. (b and c) Human HaCaT keratinocytes were incubated in DMSO or 1
µg/mL IMQ for 30 min and (b) ATP release assessed using a bioluminescence assay, and (c)
LDH release was assessed using a spectrophotometric assay. Data represents group means ±
SEM (n = 9 from three individual experiments); * P < 0.05 compared to DMSO.

22

Geraghty et al. 2017

Purinergic Signalling

Figure 3 BBG does not prevent IMQ-induced psoriasis-like inflammation.
(a) Murine J774 macrophages were incubated for 15 min at 37°C in the absence or presence
of 10 µM BBG, and then with 25 µM ethidium bromide in the absence or presence of 1 mM
ATP for 10 min at 37°C. Assays were stopped by addition of MgCl2 medium, and ethidium+
uptake was then assessed by flow cytometry. Data represents group means ± SEM (n = 3); *
P < 0.05, *** P < 0.0001 compared to corresponding basal. (b-d) AldaraTM cream
(containing 5% IMQ) was applied to one ear of BALB/c mice from day 0 to 5. Contralateral
ears were left untreated (control). Mice were injected i.p. with BBG or saline (control) on
days 0, 2, and 4. (b) Ear swelling was measured over 6 days. Data represents group means ±
SEM (n = 5 mice per treatment); ** P < 0.005 compared to BBG. (c) Ears from mice at endpoint were stained with haematoxylin and eosin, and viewed by microscopy. Each image is
representative of 5 mice per treatment. Bars represent 200 µm. (d) Epidermal thickness was
measured on histological images using ImageJ. Data represents group means ± SEM (n = 5
mice per treatment); symbols represent individual ears; *** P < 0.0001 compared to
corresponding control.

Figure 4 A-804598 does not prevent IMQ-induced psoriasis-like inflammation.
(a) Murine J774 macrophages were incubated for 15 min at 37°C in the absence or presence
of 1 µM A-804598, and then with 25 µM ethidium bromide in the absence or presence of 1
mM ATP for 10 min at 37°C. Assays were stopped by addition of MgCl2 medium, and
ethidium+ uptake was then assessed by flow cytometry. Data represents group means ± SEM
(n = 3); *** P < 0.0001 compared to corresponding basal. (b-d) AldaraTM cream (containing
5% IMQ) was applied to one ear of BALB/c mice from day 0 to 5. Contralateral ears were
left untreated (control). Mice were injected i.p. with A-804598 or DMSO (control) on days 0
and 2. (b) Ear swelling was measured over 6 days. Data represents group means ± SEM (n =
23
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5 mice per treatment). (c) Ears from mice at end-point were stained with haematoxylin and
eosin, and viewed by microscopy. Each image is representative of 5 mice per treatment. Bars
represent 200 µm. (d) Epidermal thickness was measured on histological images using
ImageJ. Data represents group means ± SEM (n = 5 mice per treatment); symbols represent
individual ears; *** P < 0.0001 compared to corresponding control.

Figure 5 Genetic deletion of P2X7 does not prevent IMQ-induced psoriasis-like
inflammation.
(a-c) AldaraTM cream (containing 5% IMQ) was applied to ears of C57BL/6 and P2X7 KO
mice from day 0 to 5. Contralateral ears were left untreated (control). (a) Ear swelling was
measured over 6 days. Data represents group means ± SEM (n = 10 mice per strain). (b) Ears
from mice at end-point were stained with haematoxylin and eosin, and viewed by
microscopy. Each image is representative of 10 mice per group. Bars represent 200 µm. (c)
Epidermal thickness was measured on histological images using ImageJ. Data represents
group means ± SEM (n = 10 mice per strain); symbols represent individual ears; *** P <
0.0001 compared to corresponding control.

Figure 6 IMQ-induced leukocyte infiltration is similar in C57BL/6 and P2X7 KO mice.
(a-d) Single whole ear cell suspensions of ears from untreated (control) and IMQ-treated
C57BL/6 and P2X7 KO mice at end-point (Fig. 5) were labelled with fluorochromeconjugated mAb and analysed by four-colour flow cytometry. Data represents total numbers
of group means ± SEM for (a) leukocytes (CD45+), (b) neutrophils (CD45+ Ly6G+ CD11b+)
(c) macrophages (CD45+ Ly6G- CD11b+), and (d) T cells (CD45+ CD3+) in each cell
suspension (n = 5 mice per group); symbols represent individual ears; ** P < 0.005, *** P <
0.0001 compared to respective control ears.
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